Monoclonal Antibody-Based Near-Infrared Cancer Phototheranostics: Emerging Strategies and Translational Perspectives
Molecular Pharmaceutics · 10.11.2026
DOI: 10.1021/acs.molpharmaceut.6c00880 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 10.11.2026. Verfasst von Soundarya S Kulkarni und 4 weiteren Autor:innen. Die Arbeit nennt 162 Literaturangaben. Gefördert von: Anusandhan National Research Foundation, Department of Science and Technology, Ministry of Science and Technology, India.
Abstract (Originalsprache)
Monoclonal Antibody-Based Near-Infrared Cancer Phototheranostics have emerged as a versatile platform for cancer phototheranostics by integrating antigen-specific targeting with spatiotemporally controlled imaging and therapy. Conjugation of monoclonal antibodies (mAb) with NIR-responsive photosensitizers enables selective tumor localization and light-triggered cytotoxicity, thereby minimizing off-target toxicity while enhancing therapeutic precision. Despite promising preclinical outcomes, clinical translation remains constrained by limited intratumoral penetration of macromolecular constructs, heterogeneous antigen expression, and restricted light delivery to deep-seated tumors. Additional challenges, large-scale manufacturing, and regulatory complexity further hinder widespread clinical adoption. This review provides a critical analysis of recent advances in NIR-based antibody phototheranostics, with emphasis on rational design parameters such as antibody selection, photosensitizer engineering, and conjugation strategies. Emerging approaches, including nanocarrier-assisted delivery, tumor microenvironment modulation, and immune checkpoint-directed combination therapies, are discussed in the context of enhancing therapeutic and translational potential. Finally, future directions focusing on activatable and tumor microenvironment-responsive probes, exploration of the NIR-II window, and optimized irradiation strategies are highlighted as key avenues to bridge the gap between preclinical promise and clinical translation.
Förderung
- Anusandhan National Research Foundation
- Department of Science and Technology, Ministry of Science and Technology, India
Zitieren
APA
Kulkarni, S. S., Shah, A., Kumar, B. V., Srivastava, N., & Meher, N. (2026). Monoclonal Antibody-Based Near-Infrared Cancer Phototheranostics: Emerging Strategies and Translational Perspectives. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.6c00880
Vancouver
Kulkarni SS, Shah A, Kumar BV, Srivastava N, Meher N. Monoclonal Antibody-Based Near-Infrared Cancer Phototheranostics: Emerging Strategies and Translational Perspectives. Molecular Pharmaceutics. 2026. doi:10.1021/acs.molpharmaceut.6c00880
BibTeX
@article{Kulkarni2026,
author = {Kulkarni, Soundarya S and Shah, Aakash and Kumar, Boga Vijay and Srivastava, Nidhi and Meher, Niranjan},
title = {Monoclonal Antibody-Based Near-Infrared Cancer Phototheranostics: Emerging Strategies and Translational Perspectives},
journal = {Molecular Pharmaceutics},
year = {2026},
doi = {10.1021/acs.molpharmaceut.6c00880}
}
EUVIMED